SP-TRAVIR-1

Travirtide (RUO)

US$247.00 US$195.00

In stock

Description

About Travirtide (RUO)

Travirtide (RUO) - Specifications

  • Amount: 0.5 mg net (AAA)
  • Purity: Research Use Only: >95% (HPLC/MS)
  • Counterion: chloride
  • Delivery Format: Freeze-dried in plastic vial
  • MW (average): 1440.75
  • Application(s): T-cell immunity, Transduction
  • Condition(s)/Topic(s): Cancer, Infection, Gene therapy, non-Hodgkin lymphoma
  • Standard Delivery Time: 2-5 days

Are you interested in other peptides or conjugation to a protein, nucleic acid or lipid? Choose your sequence, amount and purity with our Custom Peptide Synthesis services.

Background of Viral Transduction Enhancers

Gene transfer into T cells, hematopoietic stem cells or other cells via viral vectors is a widely used technique in modern biology laboratories. It can be used in research projects, e.g. the validation of disease targets, as well as in the development of therapeutics for infectious diseases or cancer. One practical example are cellular immunotherapies involving T-cells with chimeric antigen receptors (CAR-Ts) or engineered T-cell receptors (TCR-Ts) have led to promising new cancer treatments. However, due to the complex manufacturing process, these therapies are still very costly. A critical step is gene transfer, which often relies on retroviral vectors and is often hampered by low transduction rates. To address this, a number of transduction enhancers have been developed, but with variable success. These include surfactants, fibril-forming or amphipathic peptides, and coating of cultureware, which is cumbersome due to time-consuming liquid handling steps.

Benefits of JPT’s Transduction Enhancer Travirtide

Travirtide is a highly potent transduction enhancer for viral gene transfer. The peptide is designed to enhance transduction with various retroviral vectors. It promotes viral vector entry into mammalian cells via a rapid and robust protocol. Due to its high potency, it should find wide application in transduction experiments and has the potential to reduce the cost of CAR-T cell production.
  • Strong transduction enhancement (see poster)
  • Higher transduction efficacy than competitors (see poster)
  • Low cytotoxicity
  • Good aqueous solubility
  • No preservatives added
Make sure to take a look at our conference poster about Travirtide™!

References

References for Travirtide (RUO)

  1. Kaygisiz, K. et al., Materials promoting viral gene delivery. Biomater. Sci. (2020)
  2. Forssmann, W.G., Zgraja, A., Protransduzin-B, A gene transfer enhancer, WO2014177635A1.
  3. Fenard, D. et al., Vectofusin 1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Mol. Ther. Nucleic Acids (2013)
  4. Lamers, C. H, et al., Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield. Cytotherapy (2008)
  5. Schnatbaum, K. et al., A New Highly Potent Transduction Enhancer Peptideto Accelerate CAR-T Production. CIMT Conference poster (2025)

Documentation

Documentation for Travirtide (RUO)

Properties

Properties of Travirtide (RUO)

Properties Values
Amount: 0.5 mg net (AAA)
Application: T-cell immunity, Transduction
Category: Single Peptide
Condition / Topic: Cancer, Gene therapy, Infection, non-Hodgkin lymphoma
Layout: Freeze-dried in plastic vial
Organism: Artificial
Protein Name: Other
Purity: Research Use Only: >95% (HPLC/MS)
Quantification: No
Loading...

Check our list of products, click and go.

Get a quote